Gilead Sciences Inc. (GILD)
Gilead Sciences (GILD) Falls More Steeply Than Broader Market: What Investors Need to Know
In the closing of the recent trading day, Gilead Sciences (GILD) stood at $141.29, denoting a -2.15% move from the preceding trading day.
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 Transcript
Gilead Sciences, Inc. (GILD) Presents at Leerink Global Healthcare Conference 2026 Transcript
Gilead Sciences (GILD) Outperforms Broader Market: What You Need to Know
Gilead Sciences (GILD) reached $146.63 at the closing of the latest trading day, reflecting a +1.88% change compared to its last close.
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Gilead Sciences (GILD) Registers a Bigger Fall Than the Market: Important Facts to Note
In the latest trading session, Gilead Sciences (GILD) closed at $147.83, marking a -1.46% move from the previous day.
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Gilead Sciences, Inc. (GILD) Presents at TD Cowen 46th Annual Health Care Conference Transcript
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Gilead's experimental HIV treatment shows low discontinuation rates in studies
Gilead Sciences on Wednesday said its experimental single-tablet HIV treatment was generally well tolerated with low discontinuation rates, positioning the single-tablet regimen as a potential option for patients to switch to after the virus is already suppressed.
GILD to Acquire ACLX for $7.8B & Gain Full Control of Anito-Cel
Gilead is set to acquire Arcellx for $7.8B, gaining full control of anito-cel and boosting its cell therapy pipeline amid rising competition.
Gilead pays $7.8bn to take full control of promising multiple myeloma therapy
Gilead Sciences Inc (NASDAQ:GILD, XETRA:GIS) has agreed to buy Arcellx in a deal valuing the clinical-stage biotechnology company at $7.8 billion, converting an existing partnership into outright ownership of a CAR T-cell therapy that could be approved by US regulators before the end of this year. The offer of $115 per share in cash represents a 68% premium to Arcellx's 30-day volume-weighted average share price as of 20 February.
Gilead shows its belief in its partner's cancer treatment with a $7.8 billion buyout
Shares of Arcellx shot up toward a fresh record in early Monday trading, after Gilead Sciences agreed to buy the rest of the shares it doesn't already own of the biotechnology company, in a deal with an equity value of $7.8 billion.
